Literature DB >> 32794061

Characteristics and prognosis of 17 special histologic subtypes of invasive breast cancers according to World Health Organization classification: comparative analysis to invasive carcinoma of no special type.

Jiyoung Kim1, Jee Ye Kim2, Han-Byoel Lee3, Young Joo Lee4, Min-Ki Seong5, Namsun Paik6, Woo-Chan Park7, Sungmin Park8, Seung Pil Jung9, Soo Youn Bae10.   

Abstract

BACKGROUND: Breast cancer is a heterogeneous disease with various histopathologic subtypes. Except for invasive carcinoma of no special type (NST), other subtypes are rare with limited data. The purpose of this study was to analyze the characteristics and prognosis of special histopathologic subtypes of breast cancer compared to NST.
METHODS: A total of 136,140 patients were analyzed using the Korean Breast Cancer Society Registry database between January 1996 and March 2019. The clinicopathologic features and survival outcomes of special type breast carcinoma were compared with those of NST.
RESULTS: The prevalence of special subtypes other than NST was 13.7% (n = 18,633). Compared to NST, patients with lobular, medullary, metaplastic, and micropapillary carcinoma had larger tumors (p < 0.001). Patients with mucinous, tubular, medullary, metaplastic, and cribriform carcinoma presented with less node metastasis (p < 0.001), contrary to patients with micropapillary carcinoma. Patients with lobular, mucinous, tubular, papillary, and cribriform carcinoma presented as luminal A subtype much more often (p < 0.001). Micropapillary carcinoma included more luminal B subtype (p < 0.001). Typically, medullary and metaplastic carcinoma included more triple-negative subtypes (p < 0.001). In survival analysis, only medullary (Hazard Ratio (HzR) 0.542, 95% CI 0.345 to 0.852, p = 0.008) and metaplastic carcinoma (HzR 1.655, 95% CI 1.317 to 2.080, p < 0.001) showed significantly different overall survival from NST by multivariate analysis.
CONCLUSION: Breast cancer had distinct clinicopathologic features according to histopathologic subtype. However, special types of breast cancer had similar survival outcomes compared to NST when adjusting for other prognostic factors, except for metaplastic carcinoma and medullary carcinoma.

Entities:  

Keywords:  Apocrine; Breast cancer; Cribriform; Histology; Lobular; Medullary; Metaplastic; Micropapillary; Mucinous; Papillary; Tubular

Year:  2020        PMID: 32794061     DOI: 10.1007/s10549-020-05861-6

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  7 in total

1.  Biomarker profile of invasive lobular carcinoma: pleomorphic versus classic subtypes, clinicopathological characteristics and prognosis analyses.

Authors:  Yu Zhang; Xiulan Luo; Min Chen; Libo Yang; Ting Lei; Tianjie Pu; Bing Wei; Hong Bu; Zhang Zhang
Journal:  Breast Cancer Res Treat       Date:  2022-06-06       Impact factor: 4.872

2.  Multi-omics analyses provide novel biological insights to distinguish lobular ductal types of invasive breast cancers.

Authors:  Ambily Sivadas; Victor C Kok; Ka-Lok Ng
Journal:  Breast Cancer Res Treat       Date:  2022-03-29       Impact factor: 4.872

3.  Sentinel lymph node metastasis diagnosis using ultrasound plus magnetic resonance lymphangiography in breast cancer.

Authors:  Yishan He; Oufei Liu; Jing Su; Qing Hong; Mengquan Li
Journal:  Gland Surg       Date:  2022-06

Review 4.  Micropapillary Breast Carcinoma: From Molecular Pathogenesis to Prognosis.

Authors:  Georgios-Ioannis Verras; Levan Tchabashvili; Francesk Mulita; Ioanna Maria Grypari; Sofia Sourouni; Evangelia Panagodimou; Maria-Ioanna Argentou
Journal:  Breast Cancer (Dove Med Press)       Date:  2022-03-12

5.  HER2-positive apocrine carcinoma of the breast: a population-based analysis of treatment and outcome.

Authors:  Faruk Skenderi; Mohamad Alhoda Mohamad Alahmad; Emin Tahirovic; Yaman M Alahmad; Zoran Gatalica; Semir Vranic
Journal:  Breast Cancer Res Treat       Date:  2022-03-30       Impact factor: 4.624

6.  A Novel Combined Nomogram Model for Predicting the Pathological Complete Response to Neoadjuvant Chemotherapy in Invasive Breast Carcinoma of No Specific Type: Real-World Study.

Authors:  Xuelin Zhu; Jing Shen; Huanlei Zhang; Xiulin Wang; Huihui Zhang; Jing Yu; Qing Zhang; Dongdong Song; Liping Guo; Dianlong Zhang; Ruiping Zhu; Jianlin Wu
Journal:  Front Oncol       Date:  2022-06-06       Impact factor: 5.738

Review 7.  PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports.

Authors:  M J M Uijen; Y H W Derks; W A M van Gemert; J Nagarajah; R I J Merkx; M G M Schilham; J Roosen; B M Privé; S A M van Lith; C M L van Herpen; M Gotthardt; S Heskamp
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-06-12       Impact factor: 9.236

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.